The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.
April 26th 2024
Rohan Garje, MD, highlights advances made in precision medicine approaches for the management of metastatic prostate cancer.
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Medical Crossfire®: Critical Questions on Diagnosis, Sequencing, and Selection of Systemic and Radioligand Therapy Options for Patients with GEP-NETs
View More
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
2023 ASCO Direct™ Highlights: Practice-Changing Data From the Leading Oncology Conference
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Prostate Cancer Has High Rate of Actionable Mutations, Underscoring Need for Testing
All patients with prostate cancer, except for those with low-risk or very low-risk localized disease, should be tested for germline mutations, and somatic testing should be done in all patients with metastatic disease as there are therapeutic implications.
Sequencing Considerations in mCRPC Treatment Grow Increasingly Complex
For patients with metastatic castration-resistant prostate cancer who experience disease progression on novel hormonal agents (NHAs) and androgen deprivation therapy, it is important to consider when the NHA was received and whether docetaxel has been administered, as these factors affect downstream options and sequencing.
Genetic Testing Proves Significant in Identifying Somatic and Germline Mutations in Prostate Cancer
November 11th 2022As the role of genetic testing in clinical practice becomes more prevalent for patients with prostate cancer to identify mutations, physicians must consider a variety of factors to determine which patients are candidates for somatic and/or germline testing.
Dr. Wee on the Current Landscape of Nonmetastatic CRPC Treatment and Classification
October 31st 2022Christopher Wee, MD discusses the current treatment landscape for nonmetastatic castration-resistant prostate cancer, and how the success of new diagnostic tools decreases the need for this classification.
Darolutamide Combination Improves OS vs Placebo in Black Patients With mHSPC
October 28th 2022Darolutamide plus androgen-deprivation therapy and docetaxel elicited an overall survival benefit over placebo plus ADT and docetaxel in Black and African American patients with metastatic hormone-sensitive prostate cancer similar to the benefit observed in the overall population of the ARASENS trial.
Radiation Plus Intermittent Hormone Therapy Improves PFS in Oligometastatic Prostate Cancer
A regimen comprised of radiation and intermittent hormone therapy (HT) resulted in an improvement in progression-free survival in patients with oligometastatic prostate cancer, according to data from the phase 2 EXTEND trial.
Cediranib Plus Olaparib Elicits rPFS Benefit in Metastatic Castration-Resistant Prostate Cancer
October 24th 2022The combination of cediranib and olaparib significantly improved radiographic progression-free survival compared with olaparib monotherapy in patients with metastatic castration-resistant prostate cancer.
Pluvicto Receives Support for European Approval in PSMA-Positive mCRPC
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of Lutetium 177 vipivotide tetraxetan in combination with androgen deprivation therapy with or without androgen receptor pathway inhibition for the treatment of adult patients with progressive prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer who have been treated with AR pathway inhibition and taxane-based chemotherapy.
Novel AR-Targeted Therapies for Metastatic Hormone-Sensitive Prostate Cancer: Which One to Choose
October 5th 2022Advances in the understanding of the genomics and biological functions of prostate cancer have resulted in the emergence of several new classes of agents that have improved outcomes in men with prostate cancer, including metastatic hormone-sensitive prostate cancer.
Talazoparib/Enzalutamide Combo Meets rPFS End Point in Untreated Metastatic CRPC
The addition of talazoparib to enzalutamide produced a statistically significant and clinically meaningful improvement in radiographic progression-free survival vs enzalutamide plus placebo in previously untreated patients with metastatic castration-resistant prostate cancer, with or without homologous recombination repair gene mutations.
Rucaparib Meets rPFS End Point in BRCA/ATM-Mutated mCRPC
Single-agent rucaparib significantly improved radiographic progression-free survival vs chemotherapy or second-line androgen deprivation therapy in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer harboring BRCA or ATM mutations.
FDA Accepts NDA for 18F-rhPSMA-7.3 as Diagnostic Imaging Tool in Prostate Cancer
September 29th 2022The FDA has accepted for review a new drug application for 18F-rhPSMA-7.3, an investigational radiohybrid PSMA-targeted PET imaging agent for diagnostic imaging of prostate cancer, according to an announcement from Blue Earth Diagnostics.
Enzalutamide Plus ADT Improves rPFS, OS in Metastatic HSPC With Prior ADT
September 20th 2022Enzalutamide plus androgen deprivation therapy elicited significant improvements in radiographic progression-free survival and overall survival vs placebo in patients with metastatic hormone-sensitive prostate cancer.
The decline of prostate-specific antigen following treatment with lutetium Lu 177 vipivotide tetraxetan plus standard of care was linked with prolonged radiographic progression-free survival and overall survival in patients with progressive prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer.